Findings

What do systematic reviews say?

2 questions · 2 findings · 2 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.34 [0.68, 2.66]
4 studies · 1586 participants
Low

Serious adverse events · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.2 [0.77, 1.87]
7 studies · 3196 participants
Moderate